Published in:
01-01-2009 | Original Article
Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data
Authors:
Nicholas J. A. Webb, Sylwester Prokurat, Karel Vondrak, Alan R. Watson, David A. Hughes, Stephen D. Marks, Nadeem E. Moghal, Maggie M. Fitzpatrick, David V. Milford, Moin A. Saleem, Caroline A. Jones, Styrbjorn Friman, Rita Van Damme-Lombaerts, Franςoise Janssen, Clare Hamer, Sarah Rhodes
Published in:
Pediatric Nephrology
|
Issue 1/2009
Login to get access
Abstract
A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n = 93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n = 99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan–Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P = 0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P = 0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m2 body surface area in the TAS arm and 66.7 ml/min per 1.73 m2 in the TAS + B arm (P = 0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.